[PSA] phase 2 is not what most of this community thinks it is
The one-line version is the title: phase 2 is not what most of this community thinks it is. The rest is why. It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it. Increases in heart rate have…
Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.
Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.
Which phase 2 arm are you quoting, and at what week?
Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.
Kept a log specifically because there is so little published. It is one person and it is not data.
Yes — the glucagon arm is what makes it a different proposition rather than a stronger version of the others.